Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al
| Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S |
| Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc. |
| 1:2022cv01125 |
| August 26, 2022 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 24, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 23 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc., Other Affiliate Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc.. (Cottrell, Frederick) |
| Filing 22 REDACTED VERSION of #19 Reply Brief re Motion to Dismiss by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Filing 21 REDACTED VERSION of #17 Declaration of Jeanette M. Roorda by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Filing 20 REDACTED VERSION of #16 Answering Brief in Opposition by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Filing 19 [SEALED] Supplemental REPLY BRIEF re #12 MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: #1 Certificate of Compliance)(Cottrell, Frederick) |
| Filing 18 NOTICE of Absence of Consent to Proceed Before A United States Magistrate Judge, by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. (Balick, Steven) |
| Filing 17 [SEALED] DECLARATION re #16 Answering Brief in Opposition (Declaration of Jeanette M. Roorda) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: #1 Exhibit A-I)(Balick, Steven) |
| Filing 16 [SEALED] ANSWERING BRIEF in Opposition re #12 MOTION to Dismiss for Improper Venue filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 10/18/2022. (Balick, Steven) |
Filing 15
ORAL ORDER: It is HEREBY ORDERED that on or before October 12, 2022, the parties shall, after meeting and conferring, complete and file the "Notice of Consent or Absence of Consent to Proceed Before A United States Magistrate Judge" that has been docketed with this Order. Ordered by Judge Colm F. Connolly on 9/28/2022. (nmf)
|
|
Filing 14
SO ORDERED, re #11 Stipulation Regarding Mylan Pharmaceutical Inc.'s and Viatris Inc.'s Response to the Complaint, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 9/27/2022. (kmd)
|
| Filing 13 Supplemental OPENING BRIEF in Support re #12 MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals Inc., Viatris Inc..Answering Brief/Response due date per Local Rules is 10/11/2022. (Attachments: #1 Certificate of Compliance)(Cottrell, Frederick) |
| Filing 12 MOTION to Dismiss for Improper Venue - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: #1 Text of Proposed Order)(Cottrell, Frederick) |
| Filing 11 STIPULATION Regarding Mylan Pharmaceutical Inc.'s and Viatris Inc.'s Response to the Complaint by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
|
SO ORDERED, re #9 STIPULATION TO EXTEND TIME to respond to the Complaint to September 26, 2022, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Reset Answer Deadlines: Mylan Pharmaceuticals Inc. answer due 9/26/2022; Viatris Inc. answer due 9/26/2022. Ordered by Judge Colm F. Connolly on 9/20/2022. (kmd)
|
| Filing 10 NOTICE of Appearance by Frederick L. Cottrell, III on behalf of Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Cottrell, Frederick) |
| Filing 9 STIPULATION TO EXTEND TIME to respond to the Complaint to September 26, 2022 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Haynes, Christine) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Filing 8 SUMMONS Returned Executed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Viatris Inc. served on 8/29/2022, answer due 9/19/2022. (Balick, Steven) |
| Filing 7 SUMMONS Returned Executed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Mylan Pharmaceuticals Inc. served on 8/29/2022, answer due 9/19/2022. (Balick, Steven) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by H. Lundbeck A/S.(mkr) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Otsuka Pharmaceutical Co., Ltd. filed by Otsuka Pharmaceutical Co., Ltd.(mkr) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number 11,344,547.(mkr) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 7/27/2022. Date of Expiration of Patent: 9/24/2033.Thirty Month Stay Deadline: 8/24/2024. (mkr) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) |
| Filing 1 COMPLAINT for PATENT INFRINGEMENT filed against Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc. ( Filing fee $ 402, receipt number ADEDC-3946348.) - filed by Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet) (mkr) |
| No Summons Issued. (mkr) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
